Characterization of species C human adenovirus serotype 6 (Ad6)

Virology

Volumn 412, Issue 1, 2011, Pages 19-27

  Weaver, Eric A ^a   Hillestad, Mathew L ^a   Khare, Reeti ^a   Palmer, Donna ^b   Ng, Philip ^b   Barry, Michael A ^a  

^a MAYO CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; Fiber; Hexon; Liver infection; Sequence; Species C

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 10; VIRUS ENVELOPE PROTEIN; VIRUS FIBER PROTEIN; VITAMIN K GROUP;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS 1; HUMAN ADENOVIRUS 2; HUMAN ADENOVIRUS 5; HUMAN ADENOVIRUS 6; HUMAN CELL; IN VITRO STUDY; MOUSE; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEROTYPE; SPECIES COMPARISON; SPECIES DIFFERENCE; SPECIES IDENTIFICATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; AMINO ACID SEQUENCE; ANIMALS; DISEASE MODELS, ANIMAL; DNA, VIRAL; GENES, REPORTER; HUMANS; LIVER; LUCIFERASES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUSCLES; PHYLOGENY; RODENT DISEASES; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; TRANSDUCTION, GENETIC; WHOLE BODY IMAGING;

ADENOVIRIDAE; HUMAN ADENOVIRUS;

EID: 79952536568     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.10.041     Document Type: Article

References (28)

1. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., Holterman L., Damen I., Vogels R., Thorner A.R., O'Brien K.L., Carville A., Mansfield K.G., Goudsmit J., Havenga M.J., Barouch D.H. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 2007, 81(9):4654-4663.
2. Alba R., Bradshaw A.C., Parker A.L., Bhella D., Waddington S.N., Nicklin S.A., van Rooijen N., Custers J., Goudsmit J., Barouch D.H., McVey J.H., Baker A.H. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114(5):965-971.
3. Capone S., Meola A., Ercole B.B., Vitelli A., Pezzanera M., Ruggeri L., Davies M.E., Tafi R., Santini C., Luzzago A., Fu T.M., Bett A., Colloca S., Cortese R., Nicosia A., Folgori A. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 2006, 80(4):1688-1699.
4. Croyle M.A., Le H.T., Linse K.D., Cerullo V., Toietta G., Beaudet A., Pastore L. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 2005, 12(7):579-587.
5. D'Ambrosio E., Del Grosso N., Chicca A., Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J. Hyg. (Lond) 1982, 89(1):155-161.
6. Doronin K., Shashkova E.V., May S.M., Hofherr S.E., Barry M.A. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther. 2009, 20(9):975-988.
7. Fisher K.D., Stallwood Y., Green N.K., Ulbrich K., Mautner V., Seymour L.W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8(5):341-348.
8. Green N.K., Herbert C.W., Hale S.J., Hale A.B., Mautner V., Harkins R., Hermiston T., Ulbrich K., Fisher K.D., Seymour L.W. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004, 11(16):1256-1263.
9. Hofherr S.E., Shashkova E.V., Weaver E.A., Khare R., Barry M.A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 2008, 16(7):1276-1282.
10. Huelsenbeck J.P., Ronquist F., Nielsen R., Bollback J.P. Bayesian inference of phylogeny and its impact on evolutionary biology. Science 2001, 294(5550):2310-2314.
11. Khare, R., et al. (2010). Increased Liver Gene Therapy by a Kupffer Cell-evading Adenovirus Vector. Molecular Therapy in review.
12. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., Nanda A., Ewald B.A., Gorgone D.A., Lifton M.A., Goudsmit J., Havenga M.J., Barouch D.H. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 2005, 79(15):9694-9701.
13. Liu, H., Jin, L., Koh, S.B., Atanasov, I., Schein, S., Wu, L., and Zhou, Z.H. Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science 329(5995), 1038-43.
14. Mok H., Palmer D.J., Ng P., Barry M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 2005, 11(1):66-79.
15. Palmer D., Ng P. Improved system for helper-dependent adenoviral vector production. Mol. Ther. 2003, 8(5):846-852.
16. Parker A.L., Waddington S.N., Nicol C.G., Shayakhmetov D.M., Buckley S.M., Denby L., Kemball-Cook G., Ni S., Lieber A., McVey J.H., Nicklin S.A., Baker A.H. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006, 108(8):2554-2561.
17. Parks R., Evelegh C., Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther. 1999, 6(9):1565-1573.
18. Piedra P.A., Poveda G.A., Ramsey B., McCoy K., Hiatt P.W. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998, 101(6):1013-1019.
19. Senac, J.S., Doronin, K., Russell, S.J., Jelinek, D.F., Greipp, P.R., and Barry, M.A. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 21(2), 179-90.
20. Shashkova E.V., May S.M., Barry M.A. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 2009, 394(2):311-320.
21. Shashkova E.V., May S.M., Doronin K., Barry M.A. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol. Ther. 2009, 17(12):2121-2130.
22. Shayakhmetov D.M., Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 2000, 74(22):10274-10286.
23. Shayakhmetov D.M., Gaggar A., Ni S., Li Z.Y., Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005, 79(12):7478-7491.
24. Thompson J.D., Higgins D.G., Gibson T.J. Improved sensitivity of profile searches through the use of sequence weights and gap excision. Comput. Appl. Biosci. 1994, 10(1):19-29.
25. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., Kostense S., Penders G., Helmus N., Koudstaal W., Cecchini M., Wetterwald A., Sprangers M., Lemckert A., Ophorst O., Koel B., van Meerendonk M., Quax P., Panitti L., Grimbergen J., Bout A., Goudsmit J., Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 2003, 77(15):8263-8271.
26. Weaver E.A., Nehete P.N., Buchl S.S., Senac J.S., Palmer D., Ng P., Sastry K.J., Barry M.A. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS ONE 2009, 4(3):e5059.
27. Weaver E.A., Nehete P.N., Nehete B.P., Buchl S.J., Palmer D., Montefiori D.C., Ng P., Sastry K.J., Barry M.A. Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. Viruses 2009, 1(3):920-938.
28. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins avb3 or avb5 promote adenovirus internalization but not virus attachment. Cell 1993, 73:309-319.